drugset / Trial / NCT01490086
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 15 mg | — |
| Subject | Brilaroxazine | Small molecule | 15 mg | — |
| Subject | Brilaroxazine | Small molecule | 30 mg | — |
| Subject | Brilaroxazine | Small molecule | 50 mg | — |